Descripción de la empresa
IN8bio, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery, development, and commercialization of gamma-delta T cell product candidates designed for the treatment of cancer and autoimmune diseases. The company functions within the Healthcare sector, specifically the Biotechnology industry, where its primary objective is advancing therapeutic innovations through rigorous clinical trial phases. As of the latest available data, the organization maintains a market capitalization of $14.08M and employs a workforce of 17 individuals, reflecting its status as a small-cap entity. These financial dimensions indicate that IN8bio, Inc. is in an early-stage growth phase where capital allocation focuses heavily on research and development rather than large-scale commercial revenue generation, a common characteristic for biotechnology firms with lead product candidates such as INB-400 currently in Phase 2 clinical trials.
Salud financiera
The financial statements for the trailing twelve months show a Net Income of $-19,440,000 and an EBITDA of $-18,090,000, while the company has reported N/A for its Revenue (TTM). The substantial gap between the reported negative net income and the less negative EBITDA suggests significant non-operating expenses or interest costs that heavily impact the bottom line, although the lack of reported revenue figures underscores the pre-commercial nature of the business model. Free Cash Flow stands at $-5,547,125, which indicates that the company is currently burning cash to fund its clinical operations and R&D activities, limiting immediate financial flexibility until product approvals or partnerships occur. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, a figure that typically reflects the accounting treatment of development costs in biotech or the absence of recognized revenue in the specific reporting period. The company holds $27.09M in cash against $2.78M in debt, resulting in a Debt to Equity ratio of 10.10, which presents a complex balance sheet picture where high leverage ratios often appear in capital-light biotech models but must be interpreted alongside the massive cash reserves. A Current Ratio of 8.82 demonstrates robust short-term liquidity, suggesting the company possesses ample liquid assets to cover its immediate obligations without immediate refinancing pressure. Finally, the Return on Equity is -92.5% and the Return on Assets is -46.6%, metrics that reveal that management is currently deploying capital to generate negative returns, a typical dynamic for clinical-stage companies prioritizing asset accumulation and trial advancement over profitability.
Evaluación de valoración
The valuation metrics present a unique profile for a loss-making biotechnology firm, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -0.95. The negative forward P/E implies that the market is pricing in future earnings recovery based on projected cash flow rather than historical profitability, highlighting the speculative nature of the investment based on expected clinical trial success. The Price to Book ratio is 0.51, indicating that the market values the company at a significant discount to its book value, which often occurs when investors account for the potential dilution from future equity financing rounds needed to sustain clinical trials. Alternative valuation metrics include a Price to Sales of N/A and an EV/EBITDA of 0.56; the low EV/EBITDA figure suggests the company's enterprise value is relatively low compared to its negative earnings, yet this metric is less reliable for pre-revenue firms and must be viewed with caution. The stock has traded between a 52-Week High of $5.82 and a 52-Week Low of $1.17, meaning the current market price sits within a wide volatility range that reflects the high uncertainty surrounding the company's clinical pipeline. The Beta is recorded at 0.04, a figure that suggests the stock's price movement has historically exhibited negligible volatility relative to the broader market, a characteristic that can sometimes be an artifact of low liquidity or extreme price suppression in small-cap biotech stocks.
Growth & Income
Regarding growth metrics, the company reports N/A for Revenue Growth (YoY) and N/A for Earnings Growth (YoY), which precludes any meaningful comparison between the speed of earnings growth versus revenue growth in the current fiscal period. Since the company does not pay a dividend, the Dividend Yield is N/A and the Payout Ratio is 0.0%, confirming that IN8bio, Inc. follows the standard biotechnology strategy of reinvesting all available capital and generated cash flow back into the business to fund further research and development. Consequently, the company's growth profile is entirely dependent on the successful progression of its product candidates through clinical trials and subsequent regulatory approval rather than organic revenue expansion or income distribution to shareholders. The overall profile presents a high-risk, high-potential scenario where the absence of dividends and reported revenue growth is directly correlated with the intense capital expenditure required to advance gamma-delta T cell therapies to the market.